Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
0.171
+0.001 (0.71%)
Nov 21, 2024, 1:17 PM EST - Market open
Company Description
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products.
Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma.
Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. The company was founded in 2007 and is headquartered in Cranford, New Jersey.
Citius Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Leonard Mazur |
Contact Details
Address: 11 Commerce Drive, First Floor Cranford, New Jersey 07016 United States | |
| Phone | 908 967 6677 |
| Website | citiuspharma.com |
Stock Details
| Ticker Symbol | CTXR |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001506251 |
| CUSIP Number | 17322U207 |
| ISIN Number | US17322U2078 |
| Employer ID | 27-3425913 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Leonard L. Mazur | Co-Founder, Chief Executive Officer, Chairman and Secretary |
| Myron Z. Holubiak | Co-Founder and Executive Vice Chairman |
| Dr. Myron S. Czuczman M.D. | Executive Vice President and Chief Medical Officer |
| Jaime Bartushak | Chief Business Officer, Chief Financial Officer and Chief Accounting Officer |
| Gary F. Talarico | Executive Vice President of Operations |
| Ilanit Allen | Vice President of Investor Relations and Corporate Communications |
| Dr. Alan Lader Ph.D. | Senior Vice President and Head of Clinical Operations and Quality Assurance |
| Dhananjay G. Wadekar | Senior Vice President of Business Strategy |
| Kelly Creighton Ph.D. | Executive Vice President of Chemistry, Manufacturing and Controls |
| Nikolas Burlew | Executive Vice President of Quality Assurance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | 8-K | Current Report |
| Nov 18, 2024 | 424B5 | Filing |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 8-K | Current Report |
| Sep 27, 2024 | 8-K | Current Report |
| Sep 13, 2024 | 8-K | Current Report |
| Sep 11, 2024 | 8-K | Current Report |
| Sep 5, 2024 | 8-K | Current Report |
| Aug 16, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 4 | Statement of changes in beneficial ownership of securities |